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NeuroblastomaNeuroblastoma cell lines are heterogeneous, comprised of at least three distinct cell phenotypes; neuroblastic
N-type cells, non-neuronal substrate-adherent S-type cells and intermediate I-type cells. N- and S-type cell
populations were enriched from the parental SH-SY5Y neuroblastoma cell line and induced to differentiate
by the addition of retinoic acid (RA), a drug used in the treatment of neuroblastoma. N- and S-type cells
were identiﬁed based on their differential expression of β-tubulin III, vimentin and Bcl-2. Store-operated
Ca2+ entry (SOCE) was then measured in proliferating and differentiated N- and S-type cell populations
and the expression of STIM1, Orai1 and TRPC1, three proteins reported to play a key role in SOCE, was determined.
InN-type cells the RA-induced switch fromproliferation to differentiationwas accompanied by a down-regulation
in SOCE. STIM1 and Orai1 expression became down-regulated in differentiated cells, consistent with their respec-
tive roles as ER Ca2+ sensor and store-operated Ca2+ channel (SOC). TRPC1 became up-regulated suggesting that
TRPC1 is not involved in SOCE, at least in differentiatedN-type cells. In S-type cells SOCE remained active following
the RA-induced switch from proliferation to differentiation and the expression of STIM1 and Orai1 remained
unchanged. TRPC1 was not expressed in S-type cells. Our results indicate that differentiation of neuronal cells is
associated with a remodelling of SOCE. Therapeutic targeting of SOCE proteins could potentially be a means of
promoting neuronal differentiation in the treatment of neuroblastoma.
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
Neuroblastoma is a childhood cancer of the sympathetic nervous
system that originates from neural crest cells [1]. Neuroblastoma tu-
mours and their derived cell lines are heterogeneous, composed of
multipotent precursor cells that give rise to distinct neural crest cell lin-
eages [2]. At least three cellular phenotypes have been identiﬁed in neu-
roblastoma cell lines; neuroblastic N-type cells, substrate-adherent
S-type cells and intermediate I-type cells [2–5]. N-type cells are imma-
ture nerve cells, precursors to the sympathoadrenal cell lineage of the
neural crest [4–6]. S-type cells are multipotent precursors to Schwann
cells, melanocytes and glial cells and form the non-neuronal lineage of
the neural crest [3,4]. I-type cells are intermediate with respect to N-
and S-type cells in terms of morphology and biochemical markers
[3,4]. I-type cells may represent either a stem cell or an intermediate
stage in the transdifferentiation between N- and S-type cells [3,7].
N-type cells are more malignant than S-type cells, which appear to be
non-malignant [5,8,9]. Retinoic acid (RA) is used in the treatment pro-
tocol for high-risk neuroblastoma patients as it inhibits proliferation
and induces differentiation of cells [10–12].: +44 191 222 7424.
se.The second messenger Ca2+ plays an essential role in the regulation
of many cellular processes [13,14], including differentiation of neuronal
cells [15,16]. Store-operated Ca2+ entry (SOCE) is a ubiquitous Ca2+ in-
ﬂux pathway through which Ca2+ enters cells via store-operated Ca2+
channels (SOCs) located in the plasma membrane (PM) in response to
depletion of endoplasmic reticulum (ER) Ca2+ stores [17,18]. Previous
work from this laboratory has shown that SOCE becomes down-
regulated in SH-SY5Y neuroblastoma cells following 9-cis retinoic acid
(9cRA)-induced differentiation [19].
The proteins STIM1, Orai1 and TRPC1 have been reported to play a
key role in SOCE [20–23]. STIM1 senses the level of Ca2+ within the
ER and re-locates to ER-PM junctions to signal store depletion and in-
duce opening of SOCs [24,25]. Orai1 forms a SOC in many cell types
and is required to reconstitute the Ca2+ release-activated Ca2+ cur-
rent (ICRAC) [21,26], the most well-deﬁned SOCE pathway. TRPC1 is
a controversial SOC candidate as literature both supports and opposes
the involvement of TRPC1 in SOCE [18,27]. TRPC1 may only function
as a SOC under certain conditions as studies have shown that TRPC1
can function as either a SOC or a receptor-operated channel (ROC)
depending on its interaction with STIM1 [28–30]. The interaction be-
tween STIM1 and TRPC1 can also require Orai1 [29,31–34]. Accumu-
lating evidence suggests that SOCs are heteromeric complexes that
can include both Orai1 and TRPC1 [29,31,33,34].
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parental SH-SY5Y neuroblastoma cell line which, although mainly
composed of N-type cells, S-type cells remain present due to the abil-
ity of cells to transdifferentiate between cell phenotypes [7,35]. Cell
populations were induced to differentiate by the addition of 9cRA
and characterised morphologically and biochemically using the neu-
ronal marker proteins β-tubulin III and Bcl-2 [36–39] and the non-
neuronal marker protein vimentin [3]. The remodelling of SOCE
observed following 9cRA-induced differentiation [19] was further
characterised in this study by determining the extent that N- and
S-type cells contribute to the down-regulation. The pattern of expres-
sion of STIM1, Orai1 and TRPC1 was also determined in proliferating
and differentiated N- and S-type cells to investigate the involvement
of these Ca2+ signalling proteins in the remodelling of SOCE.
2. Materials and methods
2.1. Materials
SH-SY5Y cells were supplied by R. Ross (Fordham University, NY,
USA). FluorSave, fura-2/AM, ionomycin and thapsigargin (TG) were
obtained from Calbiochem (Darmstadt, Germany). All other chemicals
were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise stated.
2.2. Cell culture and differentiation
SH-SY5Y, N- and S-type neuroblastoma cells were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM)/F12:1 with GlutaMAX™
(Gibco, Paisley, UK) supplementedwith foetal calf serum (10%), penicil-
lin (100 IU. ml−1) and streptomycin (100 IU.ml−1). Cells were kept at
37 °C in a humidiﬁed atmosphere of 5% CO2. SH-SY5Y cells were pas-
sagedonce aweek using 0.02% EDTA andwere not used beyond passage
28. Cells were seeded onto coverslips/dishes at least 24 h prior to the
start of treatment. For differentiation, cells were treated for 7 days
with 1 μM 9cRA. Differentiation medium was replaced every 2 days.
Proliferating (control) cells were treated identically but with an equal
volume of vehicle ethanol (0.01%) in place of 9cRA.
2.3. Enrichment for N- and S-type cells
N- and S-type cells were enriched from the parental SH-SY5Y neu-
roblastoma cell line on the basis of their differential substrate adher-
ence [8]. N-type cell populations were obtained by knocking off the
more weakly adherent cells into PBS by gentle agitation and transfer-
ring the cell suspension to a new ﬂask; S-type cell populations were
obtained by maintaining those still adhered to the ﬂask. N- and
S-type cell populations were sub-cultured in this way 8 times and
are referred to in the text as N- and S-type cells.
2.4. Immunoﬂuorescence
SH-SY5Y, N- and S-type neuroblastoma cells were ﬁxed with 4%
paraformaldehyde and permeabilised with 0.1% Triton X-100. Cells
were blocked with 5% bovine serum albumin (BSA) prior to incuba-
tion for 2 h at 4 °C with anti-β-tubulin III with Alexa Fluor 488 conju-
gate, 1:50 (Covance, NJ, USA ) and anti-vimentin with Alexa Fluor 674
conjugate, 1:50 (Santa Cruz, CA, USA). Cells were incubated with
ethidium homodimer-1 (EthD-1) at a 1:500 dilution for 10 min at
room temperature (RT). Coverslips were mounted onto glass slides
with FluorSave. Images were collected on a Zeiss LSM 510 confocal
microscope using a 40× oil immersion objective. A multi-track con-
ﬁguration was used with 488 nm and 633 nm excitation light from
an argon laser and a helium-neon laser respectively. Confocal images
were collected with the pinhole set at 1 Airy unit for Alexa Fluor 647
emission, the same optical slice (1.1 μm) was then set for the collec-
tion of Alexa Fluor 488 and EthD-1 emission.2.5. Western blotting
Cells were lysed with 4 °C buffer containing 1 mM EDTA (pH 8),
1 mM EGTA (pH 8), 1.28 mM sucrose, 2 mM Tris (pH 7.6), 10% Triton
X-100 and protease inhibitor cocktail (Roche, Hertfordshire, UK).
Cells were scraped off dishes, passed through a 20-gauge needle sev-
eral times and centrifuged at 10,000 rpm for 10 min at 4 °C. Protein
concentration was measured at 492 nm using the Coomassie Blue Re-
agent (BioRad, Hertfordshire, UK). BSA was used as a protein standard
to determine the protein concentration of samples.
SDS-PAGE was performed using the NuPAGE system (Invitrogen,
Paisley, UK). Total protein (20–40 μg) was separated by electrophore-
sis through 10% Bis-Tris gels (Invitrogen) and transferred onto nitro-
cellulose membranes (BioRad). Blots were blocked for 1 h (5% milk,
0.02% Triton X-100) and were incubated with primary antibody in in-
cubation buffer (2.5% milk) overnight at 4 °C. Primary antibodies;
anti-β-actin 1:10,000 (abcam, Cambridge, UK), anti-β-Tubulin III,
1:20,000 (Covance), anti-vimentin, 1:200, (Santa Cruz), anti-Bcl-2,
1:200 (Santa Cruz), anti-STIM1, 1:200 (BD Biosciences, NJ, USA),
anti-Orai1, 1:100 and anti-TRPC1, 1:200 (Alamone Labs, Jerusalem, Is-
rael). Blots were then incubated with either mouse or rabbit second-
ary antibody with horseradish peroxidase-conjugate (Dako, Glostrup,
Denmark) for 1 h at RT. The enhanced chemiluminescence system
was used to detect immunoreactive bands on Hyperﬁlm™ (GE
Healthcare, Buckinghamshire, UK). Band intensities were measured
using ImageJ® software. Protein levels were normalised to the levels
of β-actin.
2.6. Determination of [Ca2+]i in cell populations
SH-SY5Y, N- and S-type cells were washed in Krebs buffer (10 mM
glucose, 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4,
4.2 mM NaHCO3, 2 mM CaCl2 and 200 μM sulﬁnpyrazone, 10 mM
HEPES, pH 7.4) and loaded with the Ca2+-sensitive ﬂuorescent indi-
cator dye fura-2/AM (3 μM) for 45 min. Following loading cells
were washed in Krebs buffer and incubated for a further 20 min to
allow de-esteriﬁcation of the loaded dye. Cells were washed in
Ca2+-free Krebs buffer before being mounted into a coverslip holder
(PerkinElmer, Beaconsﬁeld, UK) and inserted into a stirred cuvette
containing Ca2+-free Krebs buffer. Before beginning each experi-
ment, an excitation wavelength scan (250–450 nm) was performed
to reveal any large inconsistency in the degree of conﬂuency and/or
dye loading. Less than 5% of coverslips were rejected on this basis.
Fura-2 ﬂuorescence was continuously monitored using a PerkinElmer
LS-50B ﬂuorimeter, with excitation and emission wavelengths of 340
and 510 nm respectively. Following the establishment of a steady
baseline TG (200 nM) was added to deplete ER Ca2+ stores. CaCl2
(2 mM) was then added back to the Ca2+-free Krebs buffer to reveal
subsequent Ca2+ entry. Ionomycin (50 μM) was added to obtain Fmax
(maximum fura-2 ﬂuorescence) and MnCl2 (1 mM) was added to
obtain FMn (ﬂuorescence after quenching of fura-2), an indirect mea-
surement of Fmin (minimum fura-2 ﬂuorescence). [Ca2+]i was calcu-
lated using PerkinElmerWinLab® software which uses the formula
of Grynkiewicz [40] which assumes a dissociation constant (Kd) of
224 nm and an instrument constant (IC) of 3.The following equations
were used; Fmin=1/IC (Fmax−FMn)+FMn and [Ca2+]i=Kd(F−Fmin)/
(Fmax−F) [40]. Each trace was calibrated individually to account for
variation in conﬂuency and/or fura-2 loading. To quantify change in
[Ca2+]i the area from each response was determined in calibrated
traces using PerkinElmerWinLab® software. The area from calibrated
DMSO control traces was subtracted from experimental (TG) traces.
2.7. Statistical analysis
Data are presented as means±SEM of at least three independent
experiments, as stated in the Results section. Comparisons between
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GraphPad Prism® software. Data presented in Table 1 were analysed
using 2-wayANOVA (after log-transformation) and general linearmodels
in R [41]. For all tests, the criterion for statistical signiﬁcance was Pb0.05.
3. Results
3.1. Enrichment for N- and S-type cells
The SH-SY5Y cell line was predominantly composed of N-type
cells (Fig. 1A). However, S-type cells were present (Fig. 1A), and in
our laboratory comprised approximately 20% of the total cellFig. 1. N- and S-type cell populations were enriched from the parental SH-SY5Y neuroblastom
SH-SY5Y cell line was predominantly composed of N-type cells though S-type cells were pre
exhibited neurite extensions of ≥50 μm in length; arrow. (E) Differentiated S-type cells. Scpopulation. For our studies N- and S-type cells were enriched from
the parental SH-SY5Y cell line (Fig. 1). In N-type cell populations
S-type cells comprised less than 3% of the total cell population, simi-
larly in S-type cells populations N-type cells comprised less than 3% of
the total cell population. Proliferating N-type cells were small with
rounded or slightly elongated cell bodies with several short, branched
neurite-like processes (Fig. 1B). N-type cells grew rapidly with a dou-
bling time of ~24 h and formed weakly adherent cellular aggregates.
Proliferating S-type cells were larger and ﬂatter than N-type cells and
exhibited strong substrate adherence (Fig. 1C). S-type cells grew
more slowly compared to N-type cells with a doubling time of
~48 h and showed contact inhibition of growth.a cell line and induced to differentiate by the addition of 1 μM 9cRA for 7 days. (A) The
sent. Proliferating (B) N-type and (C) S-type cells. (D) Differentiated N-type cells. Cells
ale bars represent 20 μm.
Fig. 2. N-type cells stained positive for a neuronal lineage marker whereas S-type cells stained positive for a non-neuronal lineage marker. Confocal micrographs showing β-tubulin
III (green), vimentin (red) and EthD-1 (blue). Cells were induced to differentiate by the addition of 1 μM 9cRA for 7 days. Proliferating (A) SH-SY5Y, (B) N-type and (C) S-type cells.
Differentiated (D) SH-SY5Y and (E) N-type cells. Vimentin in neurite extension; arrow. (F) Differentiated S-type cells. Scale bars represent 50 μm. The parental SH-SY5Y cell line
was comparable to N-type cells.
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After treatment with 9cRA, N-type cells differentiated into a
neuronal-like phenotype, exhibiting long neurite extensions (Fig. 1D,
arrow). Cells were classed as differentiated if neurite extensions were
≥50 μm in length [19,42,43]. S-type cells differentiated into a more
epithelial-like phenotype becoming larger and ﬂatter with increased
substrate adherence (Fig. 1E). RA treatment inhibits proliferation of
cells [10] and a reduction in the rate of proliferation by ~75% in
N-type cells and by ~50% in S-type cells was observed.3.3. Immunoﬂuorescent proﬁle of N- and S-type cells
In order to determine cell lineage, ﬁxed cells were stained with
antibodies directed against β-tubulin III, a component of microtu-
bules in neuronal cells [38,39] and vimentin, an intermediate ﬁlament
protein in non-neuronal cells [3]. β-tubulin III was present through-
out the cytoplasm and along neurite branches/extensions of both pro-
liferating and differentiated N-type cells; expression did not appear to
change after 9cRA-induced differentiation (Fig. 2B, E). β-tubulin III
was also present throughout the cytoplasm of S-type cells, albeit at
a weaker level compared to N-type cells (Fig. 2C, F). Vimentin was
not generally present in the cell cytoplasm of N-type cells, though it
was identiﬁed in some neurite extensions (Fig. 2E, arrow). Vimentin
was present in the cytoplasm of both proliferating and differentiated
S-type cells (Fig. 2C, F). In the parental SH-SY5Y cell line, N-type cells
formed the majority of the population but S-type cells remained pres-
ent (Fig. 2A, D).3.4. β-tubulin III, vimentin and Bcl-2 in N- and S-type cells
The expression of β-tubulin III and vimentin in N- and S-type cells
was quantiﬁed by western blot analysis. In N-type cells β-tubulin III
levels remained unchanged after 9cRA-induced differentiation, P=
0.118, n=9 (Fig. 3A,C). In S-type cells β-tubulin III was present,
though at a lower level compared to the N-type cells, and after 9cRA
treatment became down-regulated compared to proliferating S-type
cells by ~44%, Pb0.001, n=9 (Fig. 3A, C). The expression of vimentin
in S-type cells remained unchanged following 9cRA-induced differen-
tiation, P=0.879, n=8 (Fig. 3B, C). Although vimentin was identiﬁed
in some neurite extensions of N-type cells (Fig. 2E), it was not
detected by western blot (Fig. 3B). The parental SH-SY5Y cell line
was comparable to N-type cells (Fig. 3).
The expression of Bcl-2 was also determined as Bcl-2 has been
shown to increase in differentiated neuroblastoma cells [44–46].
Bcl-2 was expressed in proliferating SH-SY5Y and N-type cells and
after 9cRA-induced differentiation became up-regulated by ~50%
(P=0.020, n=6) and ~35% (P=0.027, n=7) respectively (Fig. 3B,
C). Bcl-2 expression was barely detectable in S-type cells (Fig. 3B, C).
3.5. SOCE in N- and S-type cells
Ca2+ ‘add-back’ experiments were performed on N- and S-type
cell populations to determine any changes in SOCE that may have oc-
curred in response to 9cRA-induced differentiation. Fura-2 loaded
cells in Ca2+-free buffer were stimulated with TG (200 nM) to de-
plete ER Ca2+ stores, and then CaCl2 (2 mM) was added to determine
subsequent Ca2+ entry (i.e. SOCE).
Table 1
Rates of rise of TG and Ca2+ responses in N- and S-type cells. Rates of rise of TG
(200 nM) and Ca2+ (CaCl2, 2 mM) were calculated from calibrated traces such as
those shown in Fig. 4. Data were log-transformed and 2-way ANOVA was performed
to determine the effect of differentiation and the difference between cell types. For
N-type cells; proliferating n=19, differentiated n=15. For S-type cells; proliferating
n=16, differentiated n=14.
N-type S-type
Rate of rise (μM s−1) Proliferating Differentiated Proliferating Differentiated
TG 140±0.24 2.00±0.27 2.13±0.29 3.32±0.76
Ca2+ 140±0.10 1.66±0.14 3.05±0.41 2.78±0.50
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to the addition of TGwas not signiﬁcantly different between proliferating
and differentiated cells; 9.45±0.78 μM s (n=24) vs. 7.50±0.76 μM s
(n=18), P=0.088 (Fig. 4B). However, subsequent Ca2+ entry following
add-back of Ca2+was signiﬁcantly reduced by~48% in differentiated cells
compared to proliferating cells; 14.85±1.74 μM s vs. 7.64±1.83 μM s,
P=0.002 (Fig. 4B). The SOCE pathway therefore becomes down-
regulated in differentiated N-type cells. This result is comparable to
that seen in the parental SH-SY5Y cell line (Fig. 4A), and also that previ-
ously observed in this laboratory [19].
In S-type cells the extent of depletion fromERCa2+ stores in response
to TG was not signiﬁcantly different between proliferating and differ-
entiated cells; 6.63±0.77 μM s (n=15) vs. 6.50±1.10 μM s (n=16),Fig. 3. N- and S-type cells show differential expression of β-tubulin III, vimentin and
Bcl-2. P=proliferating (vehicle EtOH), D=differentiated (1 μM 9cRA). β-actin was
used as a loading control. (A) Western blot showing expression of β-tubulin III. In dif-
ferentiated S-type cells expression became down-regulated compared to proliferating
S-type cells. (B) Western blots showing expression of vimentin and Bcl-2. Vimentin
was only detected in S-type cells. Bcl-2 expression became up-regulated in differenti-
ated SH-SY5Y and N-type cells and was barely detectable in S-type cells. (C) Histogram
showing relative expression of β-tubulin III, vimentin and Bcl-2 as a ratio of β-actin ex-
pression. The parental SH-SY5Y cell line was comparable to N-type cells.P=0.925 (Fig. 4C). Subsequent Ca2+ entry following add-back of Ca2+
was also not signiﬁcantly different betweenproliferating anddifferentiat-
ed cells; 10.15±1.48 μM s vs. 11.74±3.14 μM s, P=0.657 (Fig. 4C). The
SOCE pathway therefore remained active in differentiated S-type cells.
To understand further the relationship between store depletion
and subsequent Ca2+ entry during the switch from proliferation to
differentiation, TG responses (store depletion) were plotted against
Ca2+ responses for individual N- and S-type cell populations (Fig. 5)
and analysed using linear models to investigate the effect of TG response
and 9cRA treatment on subsequent Ca2+ entry. For N-type cells there
was a signiﬁcant effect of store depletion on Ca2+ entry (Pb0.001) and
a signiﬁcant negative effect of 9cRA treatment (i.e. reduction in the inter-
cept of the line relating TG to Ca2+ response; P=0.011) consistentwith a
down-regulation of Ca2+ entry in differentiated cells (Fig. 5A). The slopes
of the lines relating the magnitudes of store depletion to Ca2+ entry did
not differ signiﬁcantly in relation to 9cRA treatment (P=0.222). For
S-type cells, there was no statistically-signiﬁcant effect of store depletion
or 9cRA treatment on Ca2+ entry (model overall, P=0.262; TG effect,
P=0.089; 9cRA effect and interaction P=0.338) (Fig. 5C).
The rates of rise of both TG and Ca2+ responses were also deter-
mined. There was a signiﬁcant difference in the rates of rise for
store depletion (P=0.015) and Ca2+ entry (Pb0.001) between N-
and S-type cells (Table 1). However, the rates of rise for store deple-
tion and Ca2+ entry did not change signiﬁcantly in response to
9cRA treatment (store depletion, P=0.052; Ca2+ entry, P=0.944)
regardless of cell type (2-way ANOVA interaction terms, P=0.175)
(Table 1). Although the rates of rise for store depletion did not strictly
meet the criteria for statistical signiﬁcance, the rather low probability
of no effect in this case raises the possibility that 9cRA treatment may
increase sensitivity to TG in both cell types.
3.6. STIM1, Orai1 and TRPC1 in N- and S-type cells
The proteins STIM1, Orai1 and TRPC1 have previously been shown
to play a key role in SOCE [20–23]. To determine whether these pro-
teins were involved in the SOCE activity measured in N- and S-type
cells, their expression was measured by western blot analysis.
STIM1 was identiﬁed in both N- and S-type cells. After 9cRA-induced
differentiation, the level of STIM1 expression became down-regulated
by ~49%, P=0.036 in N-type cells, though remained unchanged in
S-type cells, P=0.905, n=4 (Fig. 6A,C). These changes were consis-
tent with the changes observed in SOCE (Fig. 4). Orai1 was also
identiﬁed in both N- and S-type cells. Following 9cRA-induced differ-
entiation the level of Orai1 expression became down-regulated by
~64%, P=0.038 in N-type cells, and remained unchanged in S-type
cells, P=0.661, n=4 (Fig. 6B, C). The changes observed in Orai1 ex-
pression are consistent both with the changes observed in STIM1 ex-
pression (Fig. 6A, C), and also the level of SOCE activity measured in
SH-SY5Y, N- and S-type cells (Fig. 4). TRPC1 was identiﬁed in
N-type cells (Fig. 6A, C). After 9cRA-induced differentiation TRPC1 ex-
pression became up-regulated by ~52% (P=0.032, n=3) in N-type
cells, suggesting that TRPC1 does not form a SOC in these cells since
SOCE becomes down-regulated (Fig. 4B). Though proliferating and
differentiated S-type cells display SOCE (Fig. 4C), TRPC1 was not iden-
tiﬁed in S-type cells (Fig. 6A, C). In proliferating N-type cells, a double
band was observed in response to STIM1 and TRPC1 antibodies that
was not observed in differentiated N-type cells (Fig. 6A). The parental
SH-SY5Y cell line was comparable to the N-type cells (Fig. 6A, B).
4. Discussion
Previous ﬁndings from this laboratory have shown that SOCE be-
comes down-regulated in 9cRA-differentiated SH-SY5Y neuroblasto-
ma cells [19]. The aims of this study were to characterise SOCE in N-
and S-type cell populations and to investigate the involvement of
STIM1, Orai1 and TRPC1 in relation to SOCE activity. N- and S-type
Fig. 4. SOCE pathway activity in proliferating and 9cRA differentiated N- and S-type cells. Cells were induced to differentiate by the addition of 1 μM 9cRA for 7 days. The addition of
TG (200 nM) to fura-2 loaded cells depletes ER Ca2+ stores which is observed as an increase in [Ca2+]i and the re-addition of extracellular Ca2+ (CaCl2 , 2 mM) to Ca2+-free buffer is
also observed as an increase in [Ca2+]i as Ca2+ enters the cells (calibrated traces show [Ca2+]i (40 nM) against time (200 s)); ( ) proliferating, (■) differentiated. After
9cRA-induced differentiation, SOCE became in (A) SH-SY5Y cells, signiﬁcantly down-regulated (*), in (B) N-type cells, signiﬁcantly down-regulated (*) and in (C) S-type cells,
unchanged.
648 N. Bell et al. / Biochimica et Biophysica Acta 1833 (2013) 643–651cells were enriched from the parental SH-SY5Y cell line and the ex-
pression of proteins previously shown to be speciﬁc to N and S cell
lines was determined to conﬁrm neuronal and non-neuronal lineages
respectively.
Differentiation of N- and S-type cells with 9cRA highlighted mor-
phological differences between the two cell types with N-type cells be-
coming more neuronal-like and S-type cells becoming more epithelial-
like.β-tubulin III, a microtubule protein found in neuronal cells [38,39],
was expressed in N-type cells, and expression did not change following
9cRA-induced differentiation. β-tubulin III therefore appears to be a
marker of neuronal lineage and not of differentiation itself. β-tubulin III
was also, surprisingly, expressed in S-type cells. Expression was weak
as judged by immunoﬂuorescence but clearly present as determined
by western blot. S-type cells may have only recently committed to a
non-neuronal lineage through the process of transdifferentiation [3,7].
Fig. 5. Relationship between store depletion and subsequent Ca2+ entry in ( ) prolif-
erating and (■) differentiated N- and S-type cell populations. (A) For N-type cells the
overall model was statistically signiﬁcant (Pb0.001). (B) For S-type cells the overall
model was not signiﬁcant, P=0.262. Analysis was in R.
Fig. 6. N- and S-type cells show differential expression of STIM1, Orai1 and TRPC1.
P=proliferating (vehicle EtOH), D=differentiated (1 μM 9cRA). β-actin was used
as a loading control. (A) Western blots showing expression of TRPC1 and STIM1.
TRPC1 expression became up-regulated in N-type after differentiation and was not
expressed in S-type cells. STIM1 expression became down-regulated in SH-SY5Y
and N-type cells after 9cRA-induced differentiation and remained unchanged in
S-type cells. (B) Western blot showing expression of Orai1. Orai1 expression became
down-regulated in SH-SY5Y and N-type cells after 9cRA-induced differentiation and
remained unchanged in S-type cells. (C) Histogram showing relative expression of
β-tubulin III, vimentin and Bcl-2 as a ratio of β-actin expression. The parental
SH-SY5Y cell line was comparable to N-type cells.
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differentiated S-type cells. This is consistent with S-type cells moving
away from a neuronal phenotype; it has been found that after RA
treatment S-type cells differentiate into Schwann cells [47] and
also melanocytic cells [48].
Vimentin, an intermediate ﬁlament protein found in non-neuronal
cells [3], was expressed in S-type cells. Vimentin was not generally
expressed in N-type cells but it was identiﬁed in some neurite exten-
sions. Vimentin is, however, an essential transient requirement for
the initiation of neurite outgrowth in NB2a neuroblastoma cells and
also in hippocampal neurons where knockdown of vimentin signiﬁ-
cantly inhibited neurite outgrowth [49,50].
The anti-apoptotic protein Bcl-2, which is widely expressed in sym-
pathetic neurons [37], was present in proliferating N-type cells and be-
came up-regulated in differentiated N-type cells [44–46], consistent
with the neuronal lineage of the N-type cells. Bcl-2 expression was
barely detectable in both proliferating and differentiated S-type cells.
The differential expression of β-tubulin III, vimentin and Bcl-2 ob-
served conﬁrmed the morphological and biochemical enrichment of
N- and S-type cells from the parental SH-SY5Y cell line. After enrich-
ment, SOCEwasmeasured in N- and S-type cell populations. The results
revealed that the down-regulation of SOCE previously observed in
SH-SY5Y cells [19], and also in this study, is a feature of N-type cells
and not S-type cells.The activity of the SOCE pathway was consistent with the level
of expression of STIM1 and Orai1 in both cell types. In N-type cells
SOCE became down-regulated following 9cRA-induced differentiation,
as did the expression of STIM1 and Orai1. In S-type cells SOCE remained
unchanged following 9cRA-induced differentiation, as did the expres-
sion of STIM1 and Orai1. This is consistent with STIM1 as the ER Ca2+
sensor [20,22] in both N- and S-type cells and with Orai1 forming,
at least in part, the SOC [21,22] in both N- and S-type cells. TRPC1
was present in proliferating N-type cells and expression became up-
regulated following differentiation. TRPC1 has been found to function
as a SOC when associated with STIM1 [28,30,31] and may therefore
function as a SOC in proliferating N-type cells, however this was not de-
termined. It is unlikely that TRPC1 functions as a SOC in differentiated
N-type cells as TRPC1 expression became up-regulated whereas SOCE
became down-regulated. In HEK293T cells down-regulation of STIM1
allowed TRPC1 to function as a ROC, insensitive to store depletion
[30]. If TRPC1 functions as a ROC in differentiated N-type cells this
could explain our previous observation that in 9cRA-differentiated
SH-SY5Y cells a non-SOCE pathway becomes up-regulated [19]. TRPC1
may be associated with differentiation itself; TRPC1 was required for
neurite outgrowth in differentiating PC12 cells but was independent
of SOCE [51]. TRPC1 expression was not detectable in either proliferat-
ing or differentiated S-type cells, which would indicate that TRPC1
does not function as a SOC in S-type cells. An increased expression of
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therefore also play a role in SOCE down-regulation in N-type cells.
Proliferating N- and S-type cells had similar SOCE proﬁles yet clearly
the composition of proteins varies between cell types as Orai1 expression
was generally lower in S-type cells and TRPC1 was not present. Differ-
ences in protein composition were further observed between differenti-
ated N- and S-type cells as the expression of STIM1, Orai1 and TRPC1
changed inN-type cells. SOC composition could help explain the different
rates of Ca2+ entry observed between N- and S-type cells. In S-type cells
there was no change in SOCE following differentiation, yet S-type cell
populations displayed variable SOCE activity, as judged by the scatter in
the relationship between Ca2+ release and Ca2+ entry. It may be that,
as multi-potent precursors to several cell types [3,4], S-type cells repre-
sent sub-populations with variable SOC compositions. In proliferating
N-type cells double bandswere detected by STIM1 and TRPC1 antibodies
thatwere not present in differentiatedN-type cells. One possibility is that
both STIM1 and TRPC1 exist in two states in proliferatingN-type cells and
in only one state in differentiated N-type cells. The two states detected in
proliferating cells could be as a result of covalent modiﬁcations, as has
been observed with STIM1 [54]. Clearly the functional consequence of
any covalent modiﬁcations needs to be elucidated.
In summary, our results reveal that the 9cRA-induced switch from
proliferation to differentiation in N-type cells is accompanied by a
remodelling of SOCE that is consistent with changes in the level
of expression of STIM1 and Orai1. The ﬁnding that SOCE is down-
regulated in N-type cells but not in S-type cells strongly suggests
that remodelling of Ca2+ signalling is linked to the process of neuro-
nal differentiation. That remodelling of Ca2+ signalling is a feature of
the N-type cells could have important implications for neuroblastoma
as tumourswith a predominantly N-phenotype aremore aggressive than
tumours with a predominantly S-phenotype [2]. The down-regulation of
SOCE in N-type cells may be required to either drive or maintain the
switch from proliferation to differentiation, and the roles of STIM1,
Orai1 and TRPC1 in this switch remain to be determined.Multiple studies
have implicated the involvement of SOCE proteins in proliferation
[55–58] and in differentiation [51,59,60]. It is likely that these proteins
play a role in the differentiation process itself and may therefore provide
a potential therapeutic target in the treatment of neuroblastoma.
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